Overview
Clot Retraction Time (CRT) is a diagnostic test used to evaluate the ability of a blood clot to shrink and stabilize after its initial formation. Following hemostasis, clot retraction occurs when platelets trapped in the fibrin mesh contract, pulling the edges of the injured blood vessel closer together to support tissue repair. This process helps stabilize the clot and is later followed by fibrinolysis, where the clot is enzymatically dissolved to restore blood circulation.
The CRT test assesses the integrity of platelet function, fibrinogen levels, and coagulation factors. It is particularly useful in identifying abnormalities in platelet count or function and in monitoring certain medical conditions such as disseminated intravascular coagulation (DIC), congenital platelet disorders, and fibrinogen abnormalities.
Symptoms
Abnormal clot retraction is not a disease in itself but indicates underlying disorders that present with characteristic symptoms. Patients who may undergo CRT testing often show:
- Easy bruising or frequent nosebleeds
- Excessive bleeding from minor injuries
- Prolonged clotting after surgery or trauma
- Unexplained petechiae or purpura on the skin
- Signs of anemia such as fatigue, paleness, or shortness of breath
- Thrombotic complications in cases like DIC
These symptoms prompt physicians to investigate clot retraction ability as part of a broader coagulation workup.
Causes
Abnormal CRT results are associated with several hematological and systemic conditions:
- Platelet function disorders:
- Glanzmann thrombasthenia – a congenital defect in platelet aggregation.
- Bernard-Soulier syndrome – a rare platelet adhesion disorder.
- Storage pool disease – involving defective platelet granule release.
- Thrombocytopenia: Low platelet count reduces clot retraction.
- Coagulation abnormalities: Dysfibrinogenemia, afibrinogenemia, or hypofibrinogenemia impair the fibrin mesh and reduce clot stability.
- Systemic conditions: Severe anemia (e.g., aplastic anemia, myelodysplastic syndrome) and disseminated intravascular coagulation (DIC) affect clot retraction.
- Liver disease: As the liver produces clotting factors, impaired function alters retraction.
Risk Factors
Certain conditions and circumstances increase the likelihood of abnormal clot retraction:
- Inherited platelet disorders: Individuals with congenital conditions like Glanzmann thrombasthenia or Bernard-Soulier syndrome are at lifelong risk.
- Low platelet count: Patients with thrombocytopenia due to bone marrow suppression, chemotherapy, or chronic illness.
- Fibrinogen deficiencies: Genetic or acquired deficiencies interfere with normal clot structure.
- Chronic systemic illness: Conditions like liver disease or myelodysplastic syndrome compromise clotting mechanisms.
- Patients on anticoagulant therapy: CRT is sometimes used to monitor response, although advanced platelet function assays are more common today.
Prevention
While CRT abnormalities are often linked to underlying medical conditions and cannot always be prevented, several steps help reduce risks and improve diagnostic reliability:
- Routine monitoring in at-risk patients: Regular hematological evaluation for patients with known platelet or fibrinogen disorders.
- Accurate test procedures:
- Collect 2 ml of venous blood in a plain tube.
- Place 1 ml in a glass tube at 37 °C in a water bath.
- Inspect the clot at 1, 2, 4, and 24 hours to observe retraction, quality, and lysis.
- At the end of 18–24 hours, complete retraction should be evident under normal conditions.
- Control pre-analytical errors: Proper handling, temperature control, and timely observation reduce variability in test outcomes.
- Use of complementary tests: Since CRT has limited sensitivity and specificity, advanced platelet function assays or coagulation studies should be considered for accurate diagnosis.
- Management of underlying disease: Treating systemic conditions like anemia, DIC, or liver disease can help improve clot retraction indirectly.
